SNX631
SNX631 is an orally active and selective CDK8/CDK19 inhibitor. SNX631 reduces the phosphorylation of STAT1/STAT3 S727, and upregulates miR-21-5p, miR-21-3p and miR-221 in cancer cells. SNX631 transcription-independently inhibits meiotic resumption in mouse oocytes, blocks nuclear envelope breakdown, first polar body extrusion and mitochondrial expansion and aggregation, with no cytotoxicity. SNX631, in combination with Lapatinib (HY-50898) or Trastuzumab (HY-P9907), synergistically inhibits cancer cell growth, upregulates the tumor suppressor BTG2, prevents Lapatinib-induced upregulation of oncogenic miRNAs, overcomes drug resistance, reduces the infiltration of αSMA+ stromal fibroblasts and ARG1+ M2 macrophages, and exhibits favorable biosafety. SNX631 can be used in studies related to HER2-positive breast cancer and cancer.
For research use only. We do not sell to patients.
- CAS No.: 868066-26-6
- Formula: C22H26N6O2S
- Molecular Weight:438.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
CDK8 |
CDK19 |
STAT1 |
p-STAT3 |
In Vitro
SNX631 (0.01-1 μM; 7 days) synergistically enhances the growth-inhibitory effects of lapatinib and trastuzumab in HER2+ breast cancer cell lines (HCC1954-Par, HCC1954-Res, JIMT-1, SKBR3, BT474), with combination index values ranging from 0.011 to 0.645 for lapatinib combinations and 0.381 to 0.562 for trastuzumab combinations[1].
SNX631 (0.01-1 μM; 7 days) has its synergistic growth-inhibitory interaction with lapatinib abrogated by PI3K pathway inhibition in HCC1954-Par, HCC1954-Res, and JIMT-1 HER2+ breast cancer cell lines, with combination index values ranging from 0.919 to 1.744[1].
SNX631 (500 nM; 6 h) inhibits phosphorylation of STAT1 at S727 and STAT3 at S727 in HCC1954-Par, HCC1954-Res, and JIMT-1 HER2+ breast cancer cell lines, and this inhibitory effect is enhanced when combined with lapatinib or trastuzumab[1].
SNX631 (0.01-1 μM; 7 days) has reduced growth-inhibitory activity against HCC1954-Par HER2+ breast cancer cells with BTG2 knockdown[1].
SNX631 (0.01-1 μM; 7 days) has slightly enhanced growth-inhibitory activity against HCC1954-Par HER2+ breast cancer cells with double knockout of STAT1 and STAT3, but shows no change in activity against JIMT-1 cells with the same knockout[1].
SNX631 (0.5-1.5 μM; 1-4 h) does not alter phosphorylation of PKA or ERK1/2 in mouse embryonic fibroblasts after 1 hour or 4 hours of incubation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HER2+ breast cancer cell lines (HCC1954-Par, HCC1954-Res, JIMT-1)
-
Concentration:500 nM
-
Incubation Time:6 h
-
Result:Decreased STAT1 S727 phosphorylation in all three cell lines.
Reduced STAT1 S727 phosphorylation to a greater extent when combined with lapatinib.
Enhanced reduction of STAT1 S727 phosphorylation when combined with trastuzumab compared to use alone.
Decreased STAT3 S727 phosphorylation (to a lesser extent than STAT1 phosphorylation) in all three cell lines.
Reduced STAT3 S727 phosphorylation to a greater extent when combined with lapatinib.
Enhanced reduction of STAT3 S727 phosphorylation in HCC1954-Res cells when combined with trastuzumab.
-
Cell Line:mouse embryonic fibroblasts (MEFs)
-
Concentration:0.5 μM, 1.5 μM
-
Incubation Time:1 h, 4 h
-
Result:Had no effect on phosphorylation levels of ERK1/2 or PKA in MEFs after 1 hour incubation at 0.5 μM or 1.5 μM.
Had no effect on phosphorylation levels of ERK1/2 or PKA in MEFs after 4 hours incubation at 0.5 μM or 1.5 μM.
Had no effect on total ERK1/2 levels in MEFs after 1 hour or 4 hours incubation at 0.5 μM or 1.5 μM.
In Vivo
SNX631 (250 ppm; medicated diet; continuous) plus (5 mg/kg; oral gavage; daily) alone significantly reduces tumor growth in lapatinib-resistant HER2+ breast cancer xenografts, with no apparent toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) (female, 6 weeks old)[1]
-
Dosage:500 ppm
-
Administration:medicated diet; continuous
-
Result:Significantly decreased tumor size and final tumor weights compared to vehicle control.
Strongly decreased tumor proliferation measured by Ki67 staining.
Significantly decreased the ratio of phosphorylated STAT1 S727 to total STAT1.
Strongly decreased Arginase-1 (ARG1) staining, a marker of M2 macrophages.
Showed no treatment-related toxicity based on mouse body weights.
-
Animal Model:NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) (female, 6 weeks old)[1]
-
Dosage:250 ppm (medicated diet); 5 mg/kg (oral gavage)
-
Administration:medicated diet; continuous; oral gavage; daily
-
Result:Significantly decreased tumor size and final tumor weights compared to vehicle control.
Showed no treatment-related toxicity based on mouse body weights.
Chemical Information
-
CAS No. 868066-26-6
-
Molecular Weight 438.55
-
Formula C22H26N6O2S
-
SMILES
O=C(N)C=1SC2=NC=CC(=C2C1N)N3CCN(C4=CC=C(C=C4)C(=O)N(C)C)CCC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)